We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Adipose Derived Stem Cells for Congestive Heart Failure

This study has been withdrawn prior to enrollment.
(no participants enrolled)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01502514
First Posted: December 30, 2011
Last Update Posted: July 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Instituto de Medicina Regenerativa, S.A. de C.V.
Information provided by (Responsible Party):
Ageless Regenerative Institute
  Purpose

The intent of this clinical study is to answer the questions:

  1. Is the proposed treatment safe
  2. Is treatment effective in improving the disease pathology of patients with Heart Disease as assessed by a series of measurements indicating improvement, stability, or degradation of a patient's cardiovascular function and exercise capacity?

Condition Intervention Phase
Ischemic Congestive Heart Failure Procedure: Fat Harvesting and Implantation of Adipose Derived Stem Cells Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Intramyocardial and Intravenous Implantation of Autologous Adipose-Derived Stem Cells in Ischemic Congestive Heart Failure Patients

Resource links provided by NLM:


Further study details as provided by Ageless Regenerative Institute:

Primary Outcome Measures:
  • Improvement in 6 Minute Walk Test [ Time Frame: 3 months ]
  • Improvement in the Minnesota Living with Heart Failure Quality of Life Questionnaire [ Time Frame: 3 months ]
  • Improvement in 6 Minute Walk Test [ Time Frame: 6 months ]
  • Improvement in the Minnesota Living with Heart Failure Quality of Life Questionnaire [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Improvement in New York Heart Association classification [ Time Frame: 3 months ]
  • Improvement in the Left Ventricular Ejection Fraction (LVEF) [ Time Frame: 3 months ]
    Determined by an echo

  • Improvement inn the Left Ventricular Volume [ Time Frame: 3 months ]
  • Improvement in New York Heart Association classification [ Time Frame: 6 months ]
  • Improvement in the Left Ventricular Ejection Fraction (LVEF) [ Time Frame: 6 months ]
  • Improvement in the Left Ventricular Volume [ Time Frame: 6 months ]

Enrollment: 0
Study Start Date: May 2011
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Fat Harvesting and Implantation of Adipose Derived Stem Cells
    Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
    Other Names:
    • Liposuction
    • ADSC
    • ASC
    • Stem Cell therapy
    • Catheterization
Detailed Description:
This will be an open-label, non-randomized, multi-center patient-sponsored study designed to assess the safety and cardiovascular effects of Adipose-derived Stem Cell (ASC) implantation using a catheter delivery system in patients who have experienced myocardial infarction. A percutaneous transluminal endomyocardial injection catheter will be used for delivery of ASCs. The therapy is composed of cells isolated from a patient's own adipose tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Willing and able to sign informed consent
  2. Age >18 years and < 80 years
  3. New York Heart Association (NYHA) Class II-IV
  4. Ischemic cardiomyopathy without an acute coronary syndrome during the prior 6 months
  5. Left Ventricular Ejection Fraction (LVEF) less than or equal to 40% measured by echocardiography at both local and investigative sites, AND:

    • Well-demarcated region of LV systolic dysfunction.
    • Left ventricular wall without mural thrombus and of thickness greater than 0.5 cm
    • No significant valvular disease including: Moderate-to-severe mitral regurgitation (3-4+), aorticstenosis (valve area <1.5 cm2), aortic insufficiency (3-4+)
  6. Up to date on all age and gender appropriate cancer screening per American Cancer Society

Exclusion Criteria:

  1. Limiting symptoms due to non-CHF causes, such as lung disease, peripheral vascular disease, arthritis or other musculoskeletal disorders
  2. Inability to complete a 6-minute walk test for any reason
  3. Need for intravenous CHF medications, chronic continuous oxygen therapyor oral steroids,
  4. Coronary Artery Bypass Graft (CABG) surgery within 60 days prior to screening
  5. Planned revascularization within 4 months following enrollment
  6. Aortic aneurysm or dilatation (>3.8 cm by echocardiography or other imaging modality)
  7. Peripheral vascular disease at or below the distal aorta that may interfere with catheter use
  8. Hemodynamically significant pericardial disease
  9. Prior aortic or mitral valve replacement
  10. Biventricular pacing device implant within the last 3 months OR whose device is scheduled to be revised following enrollment in this trial
  11. Scheduled to receive or history of cardiac transplant, surgical remodeling procedure, left ventricular assist device
  12. Stroke within 180 days of screening
  13. Positive pregnancy test in women of child bearing potential or who are unwilling to use an acceptable method of contraception.
  14. Drug or alcohol dependence
  15. Life expectancy of less than 1 year
  16. History of cancer (other than non-melanoma skin cancer or in situ cervical cancer) in the last five years
  17. Exposure to angiogenic therapy (including myocardial laser) or another investigational drug within 60 days of screening, or enrollment in any concurrent study that may confound the results of this study
  18. Any factors in the opinion of the Investigator which render the patient unsuitable for participation that will interfere with conduct of the study or interpretation of the results.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01502514


Locations
Mexico
Instituto de Medicina Regenerativa
Tijuana, Baja California, Mexico, 22010
Sponsors and Collaborators
Ageless Regenerative Institute
Instituto de Medicina Regenerativa, S.A. de C.V.
Investigators
Principal Investigator: Juan J Parcero, MD Instituto de Medicina Regenerativa
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ageless Regenerative Institute
ClinicalTrials.gov Identifier: NCT01502514     History of Changes
Other Study ID Numbers: ADI-ME-CHF-002
First Submitted: December 27, 2011
First Posted: December 30, 2011
Last Update Posted: July 21, 2017
Last Verified: July 2017

Keywords provided by Ageless Regenerative Institute:
CHF
ischemia
Heart Failure

Additional relevant MeSH terms:
Heart Failure
Ischemia
Heart Diseases
Cardiovascular Diseases
Pathologic Processes